Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
暂无分享,去创建一个
P. Whelton | Mahboob Rahman | W. Cushman | A. Cheung | M. Conroy | T. Greene | D. Kitzman | B. Freedman | W. Haley | J. Lash | S. Beddhu | G. Chertow | V. Papademetriou | C. Rosendorff | R. Pisoni | Suzanne G. Watnick | R. Campbell | Guo Wei | J. Whittle | Suzanne G Watnick | Edward J. Horwitz | Erik Riessen | Suzanne Watnick | Glenn M. Chertow | Mahboob Rahman | Alfred K. Cheung | Tom Greene | Ruth C. Campbell | Margaret Conroy | Barry I. Freedman | William Haley | Edward Horwitz | Clive Rosendorff | Suzanne G. Watnick
[1] Deepak L. Bhatt,et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.
[2] J. Coresh,et al. 60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program , 2016, Journal of the American College of Cardiology.
[3] Lenore J Launer,et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.
[4] Ji-Guang Wang,et al. The J-Curve Phenomenon in Hypertension , 2016, Pulse.
[5] M. Woodward,et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.
[6] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[7] K. Kalantar-Zadeh,et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. , 2014, Journal of the American College of Cardiology.
[8] Walter T Ambrosius,et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) , 2014, Clinical trials.
[9] Harry Hemingway,et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people , 2014, The Lancet.
[10] Mahboob Rahman,et al. Limitations of Analyses Based on Achieved Blood Pressure: Lessons From the African American Study of Kidney Disease and Hypertension Trial , 2011, Hypertension.
[11] S. Bangalore,et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.
[12] N J Wald,et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.
[13] H. Ueshima,et al. Relation of Blood Pressure and All-Cause Mortality in 180 000 Japanese Participants: Pooled Analysis of 13 Cohort Studies , 2008, Hypertension.
[14] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[15] W. Elliott. On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension , 2008 .
[16] Gina Soriya,et al. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? , 2007 .
[17] C. McCulloch,et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. , 2005, Archives of internal medicine.
[18] S. Lewington. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .
[19] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[20] W. Cushman,et al. The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.
[21] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[22] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[23] P. Whelton,et al. Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.
[24] C. Mulrow,et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.
[25] J. Cruickshank,et al. BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.